Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 2/20 | 0.36 |
| ▸ | ANPEP | P15144 | 2/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12192545 | 1.00 | MMP2 (0.36) | MMP2ANPEPATM | |
| SCHEMBL12192557 | 0.84 | ATM (0.35) | MMP2ANPEPATM | |
| SCHEMBL12192550 | 0.84 | ATM (0.35) | MMP2ANPEPATM | |
| SCHEMBL12192551 | 0.79 | ATM (0.34) | MMP2ANPEPATM | |
| SCHEMBL12192539 | 0.77 | ATM (0.33) | MMP2ANPEPATM | |
| SCHEMBL12192533 | 0.77 | ATM (0.33) | MMP2ANPEPATM | |
| SCHEMBL12192543 | 0.76 | MMP2 (0.33) | MMP2ANPEPATM | |
| SCHEMBL24785773 | 0.72 | GAA (0.31) | — | |
| SCHEMBL25540051 | 0.72 | GAA (0.31) | — | |
| SCHEMBL26265836 | 0.72 | GAA (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030495-B2 | Cyclopropyl pyrrolidine orexin receptor antagonists | MERCK SHARP & DOHME CORP. | 2011-10-04 | — | — | US | disclosed |
| US-20100152191-A1 | CYCLOPROPYL PYRROLIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152191-A1 | CYCLOPROPYL PYRROLIDINE OREXIN RECEPTOR ANTAGONISTS | HCRTR1, HCRTR2, OXTR | MMP2 3423/4885ANPEP 560/4885ATM 4835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.